<p>加利福尼亚州帕洛阿尔托 --（商业资讯）--Guardant Health, Inc.（纳斯达克：GH），一家领先的精准肿瘤学公司，今天宣布，Guardant 董事会的薪酬委员会于 2026 年 4 月 21 日批准向 267 名新非执行员工授予代表 143,898 股普通股的限制性股票单位（“RSUs”），授予日期为 2026 年 5 月 11 日，依据 Guardant Health, Inc. 2023 年就业诱导激励奖励计划（“诱导计划”）。这些 RSUs 作为员工与 Guardant 签订雇佣合同的重要诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>诱导计划专门用于向之前未曾是 Guardant 员工的个人授予股权奖励，或在经过真实的非雇佣期后，作为这些个人与 Guardant 签订雇佣合同的重要诱因，依据纳斯达克上市规则 5635(c)(4)。</p>
<p>每个 RSU 奖励所对应的股份三分之一将在每年授予开始日期的周年日按年归属，前提是每位员工在每个归属日期仍继续在 Guardant 工作。这些 RSUs 受诱导计划的条款和条件以及涵盖该授予的 RSU 奖励协议的条款和条件的约束。</p>
<p><strong>关于 Guardant Health</strong></p>
<p>Guardant Health 是一家领先的精准肿瘤学公司，专注于保护健康，让每个人都能拥有更多无癌的时间。Guardant 成立于 2012 年，通过提供对疾病驱动因素的关键洞察，利用其先进的血液和组织检测、真实世界数据和人工智能分析，正在改变患者护理并加速新的癌症疗法。Guardant 的检测有助于改善各个阶段的护理结果，包括早期筛查癌症、监测早期癌症的复发以及为晚期癌症患者选择治疗方案。有关更多信息，请访问 guardanthealth.com，并在 LinkedIn、X（推特）和 Facebook 上关注该公司。</p>
<p><strong>Guardant Health 前瞻性声明</strong></p>
<p>本新闻稿包含根据联邦证券法的定义的前瞻性声明，包括关于 Guardant Health 的液体活检测试或检测的潜在用途、价值、益处和优势的声明，这些声明涉及风险和不确定性，可能导致实际结果与这些前瞻性声明中表达的预期结果和期望存在重大差异。这些声明基于当前的期望、预测和假设，实际结果可能因多种因素而与这些声明存在重大差异。这些以及可能影响 Guardant Health 财务和运营结果的其他风险和不确定性，以及导致实际结果与本新闻稿中所作的前瞻性声明所指示的结果存在重大差异的因素，包括在其截至 2025 年 12 月 31 日的 10-K 表格年度报告及其向证券交易委员会提交或提供的其他报告中讨论的 “风险因素” 和 “管理层对财务状况和经营结果的讨论与分析” 部分。本文中的前瞻性声明基于 Guardant Health 截至本日期的信息，Guardant Health 不承担更新任何前瞻性声明的义务，以反映其期望的任何变化或任何此类声明所基于的事件、条件或情况的变化，法律要求的除外。这些前瞻性声明不应被视为代表 Guardant Health 在本新闻稿日期之后的任何日期的观点。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MTg5NzAwNDNyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MTg5NzAwNDNyMQ"/></p>
<p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20260518970043/en/</p>
<p><strong>投资者联系：</strong> Zarak Khurshid</p>
<p>investors@guardanthealth.com</p>
<p><strong>媒体联系：</strong> Meaghan Smithpress@guardanthealth.com</p>
<p>来源：Guardant Health, Inc.</p>

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Guardant Health, Inc. 宣布根据 2023 年就业诱导激励奖励计划，批准 267 名新非高管员工的限制性股票单位（RSUs），总计 143,898 股。这些作为就业诱导的 RSUs 将在三年内每年归属一次。此举符合纳斯达克上市规则 5635(c)(4)</p>

<p>PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>加利福尼亚州帕洛阿尔托 --（商业资讯）--Guardant Health, Inc.（纳斯达克：GH），一家领先的精准肿瘤学公司，今天宣布，Guardant 董事会的薪酬委员会于 2026 年 4 月 21 日批准向 267 名新非执行员工授予代表 143,898 股普通股的限制性股票单位（“RSUs”），授予日期为 2026 年 5 月 11 日，依据 Guardant Health, Inc. 2023 年就业诱导激励奖励计划（“诱导计划”）。这些 RSUs 作为员工与 Guardant 签订雇佣合同的重要诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>诱导计划专门用于向之前未曾是 Guardant 员工的个人授予股权奖励，或在经过真实的非雇佣期后，作为这些个人与 Guardant 签订雇佣合同的重要诱因，依据纳斯达克上市规则 5635(c)(4)。</p>
</div><p>One-third of the shares underlying each RSU award vest on an annual basis on the anniversary of the vesting commencement date, subject to each employee’s continued employment with Guardant as of each such vesting date. The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.</p>
<div class="lb-trans"><p>每个 RSU 奖励所对应的股份三分之一将在每年授予开始日期的周年日按年归属，前提是每位员工在每个归属日期仍继续在 Guardant 工作。这些 RSUs 受诱导计划的条款和条件以及涵盖该授予的 RSU 奖励协议的条款和条件的约束。</p>
</div><p><strong>About Guardant Health</strong></p>
<div class="lb-trans"><p><strong>关于 Guardant Health</strong></p>
</div><p>Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.</p>
<div class="lb-trans"><p>Guardant Health 是一家领先的精准肿瘤学公司，专注于保护健康，让每个人都能拥有更多无癌的时间。Guardant 成立于 2012 年，通过提供对疾病驱动因素的关键洞察，利用其先进的血液和组织检测、真实世界数据和人工智能分析，正在改变患者护理并加速新的癌症疗法。Guardant 的检测有助于改善各个阶段的护理结果，包括早期筛查癌症、监测早期癌症的复发以及为晚期癌症患者选择治疗方案。有关更多信息，请访问 guardanthealth.com，并在 LinkedIn、X（推特）和 Facebook 上关注该公司。</p>
</div><p><strong>Guardant Health Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>Guardant Health 前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2025 and in its other reports filed with or furnished to the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.</p>
<div class="lb-trans"><p>本新闻稿包含根据联邦证券法的定义的前瞻性声明，包括关于 Guardant Health 的液体活检测试或检测的潜在用途、价值、益处和优势的声明，这些声明涉及风险和不确定性，可能导致实际结果与这些前瞻性声明中表达的预期结果和期望存在重大差异。这些声明基于当前的期望、预测和假设，实际结果可能因多种因素而与这些声明存在重大差异。这些以及可能影响 Guardant Health 财务和运营结果的其他风险和不确定性，以及导致实际结果与本新闻稿中所作的前瞻性声明所指示的结果存在重大差异的因素，包括在其截至 2025 年 12 月 31 日的 10-K 表格年度报告及其向证券交易委员会提交或提供的其他报告中讨论的 “风险因素” 和 “管理层对财务状况和经营结果的讨论与分析” 部分。本文中的前瞻性声明基于 Guardant Health 截至本日期的信息，Guardant Health 不承担更新任何前瞻性声明的义务，以反映其期望的任何变化或任何此类声明所基于的事件、条件或情况的变化，法律要求的除外。这些前瞻性声明不应被视为代表 Guardant Health 在本新闻稿日期之后的任何日期的观点。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA1MTg5NzAwNDNyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260518970043r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260518970043/en/</p>
<div class="lb-trans"><p>查看商业资讯上的源版本：https://www.businesswire.com/news/home/20260518970043/en/</p>
</div><p><strong>Investor Contact:</strong> Zarak Khurshid</p>
<div class="lb-trans"><p><strong>投资者联系：</strong> Zarak Khurshid</p>
</div><p>investors@guardanthealth.com</p>
<div class="lb-trans"><p>investors@guardanthealth.com</p>
</div><p><strong>Media Contact:</strong> Meaghan Smithpress@guardanthealth.com</p>
<div class="lb-trans"><p><strong>媒体联系：</strong> Meaghan Smithpress@guardanthealth.com</p>
</div><p>Source: Guardant Health, Inc.</p>
<div class="lb-trans"><p>来源：Guardant Health, Inc.</p>
</div>

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News

StockTitan

Guardant Health

医药突破 ETF - ALPS

基因免疫&健康关怀 ETF - iShares

基因改革 ETF - ARK

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

Guardant Health 宣布根据纳斯达克上市规则 5635(c)(4) 进行激励授予 | GH 股票新闻